Harnessing the protective potential of HIV-1 neutralizing antibodies

F1000Research

Volumn 5, Issue , 2016, Pages

  Derdeyn, Cynthia A ^a,b   Smith, S Abigail ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84970951351     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.7254.1     Document Type: Review

References (73)

1. Weiss RA Clapham PR Cheingsong-Popov R : Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature. 1985;316(6023):69-72. 2989706 10.1038/316069a0
2. Rerks-Ngarm S Pitisuttithum P Nitayaphan S : Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209-20. 19843557 10.1056/NEJMoa0908492 F1000 Recommendation
3. Haynes BF Gilbert PB McElrath MJ : Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275-86. 22475592 10.1056/NEJMoa1113425 3371689 F1000 Recommendation
4. Montefiori DC Karnasuta C Huang Y : Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis. 2012;206(3):431-41. 22634875 10.1093/infdis/jis367 3392187
5. Golding H D'Souza MP Bradac J : Neutralization of HIV-1. AIDS Res Hum Retroviruses. 1994;10(6):633-43. 10.1089/aid.1994.10.633
6. Matthews TJ : Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res Hum Retroviruses. 1994;10(6):631-2. 8074926 10.1089/aid.1994.10.631
7. Mascola JR Snyder SW Weislow OS : Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis. 1996;173(2):340-8. 8568294 10.1093/infdis/173.2.340
8. Sanders RW van Gils MJ Derking R : HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science. 2015;349(6244):aac4223. 26089353 10.1126/science.aac4223 4498988
9. Kwong PD Wyatt R Majeed S : Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure. 2000;8(12):1329-39. 11188697 10.1016/S0969-2126(00)00547-5
10. Kwong PD Doyle ML Casper DJ : HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature. 2002;420(6916):678-82. 12478295 10.1038/nature01188
11. Guttman M Cupo A Julien JP : Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env. Nat Commun. 2015;6:6144. 25652336 10.1038/ncomms7144 4338595
12. Moore PL Williamson C Morris L : Virological features associated with the development of broadly neutralizing antibodies to HIV-1. Trends Microbiol. 2015;23(4):204-11. 25572881 10.1016/j.tim.2014.12.007 4380704
13. Hraber P Seaman MS Bailer RT : Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS. 2014;28(2):163-9. 24361678 10.1097/QAD.0000000000000106 4042313
14. Gray ES Madiga MC Hermanus T : The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4 + T cell decline and high viral load during acute infection. J Virol. 2011;85(10):4828-40. 21389135 10.1128/JVI.00198-11 3126191
15. Simek MD Rida W Priddy FH : Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol. 2009;83(14):7337-48. 19439467 10.1128/JVI.00110-09 2704778 F1000 Recommendation
16. Eroshkin AM LeBlanc A Weekes D : bNAber: database of broadly neutralizing HIV antibodies. Nucleic Acids Res. 2014;42(Database issue):D1133-9. 24214957 10.1093/nar/gkt1083 3964981
17. Scharf L Wang H Gao H : Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env. Cell. 2015;162(6):1379-90. 26359989 10.1016/j.cell.2015.08.035 4587768
18. McLellan JS Pancera M Carrico C : Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature. 2011;480(7377):336-43. 22113616 10.1038/nature10696 3406929 F1000 Recommendation
19. Julien JP Sok D Khayat R : Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog. 2013;9(5):e1003342. 23658524 10.1371/journal.ppat.1003342 3642082
20. Blattner C Lee JH Sliepen K : Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity. 2014;40(5):669-80. 24768348 10.1016/j.immuni.2014.04.008 4057017 F1000 Recommendation
21. Huang J Kang BH Pancera M : Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature. 2014;515(7525):138-42. 25186731 10.1038/nature13601 4224615 F1000 Recommendation
22. McGuire AT Hoot S Dreyer AM : Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med. 2013;210(4):655-63. 23530120 10.1084/jem.20122824 3620356
23. McGuire AT Glenn JA Lippy A : Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. J Virol. 2014;88(5):2645-57. 24352455 10.1128/JVI.03228-13 3958080
24. Jardine J Julien JP Menis S : Rational HIV immunogen design to target specific germline B cell receptors. Science. 2013;340(6133):711-6. 23539181 10.1126/science.1234150 3689846
25. Hoot S McGuire AT Cohen KW : Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog. 2013;9(1):e1003106. 23300456 10.1371/journal.ppat.1003106 3536657
26. Sliepen K Medina-Ramírez M Yasmeen A : Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers. Virology. 2015;486:116-20. 26433050 10.1016/j.virol.2015.08.002
27. Doria-Rose NA Schramm CA Gorman J : Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014;509(7498):55-62. 24590074 10.1038/nature13036 4395007 F1000 Recommendation
28. Liao HX Lynch R Zhou T : Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 2013;496(7446):469-76. 23552890 10.1038/nature12053 3637846 F1000 Recommendation
29. Bhiman JN Anthony C Doria-Rose NA : Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat Med. 2015;21(11):1332-6. 26457756 10.1038/nm.3963 4637988 F1000 Recommendation
30. Gao F Bonsignori M Liao HX : Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. Cell. 2014;158(3):481-91. 25065977 10.1016/j.cell.2014.06.022 4150607
31. Walker LM Huber M Doores KJ : Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477(7365):466-70. 21849977 10.1038/nature10373 3393110
32. Scheid JF Mouquet H Feldhahn N : Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009;458(7238):636-40. 19287373 10.1038/nature07930 F1000 Recommendation
33. Derdeyn CA Moore PL Morris L : Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection. Curr Opin HIV AIDS. 2014;9(3):210-6. 24662931 10.1097/COH.0000000000000057 4068799
34. Dosenovic P von Boehmer L Escolano A : Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell. 2015;161(7):1505-15. 26091035 10.1016/j.cell.2015.06.003 4604566
35. Jardine JG Ota T Sok D : HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science. 2015;349(6244):156-61. 26089355 10.1126/science.aac5894 4669217
36. Kraft Z Derby NR McCaffrey RA : Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. J Virol. 2007;81(12):6402-11. 17392364 10.1128/JVI.00424-07 1900107
37. Francica JR Sheng Z Zhang Z : Analysis of immunoglobulin transcripts and hypermutation following SHIV AD8 infection and protein-plus-adjuvant immunization. Nat Commun. 2015;6:6565. 25858157 10.1038/ncomms7565 4403371
38. Shingai M Donau OK Schmidt SD : Most rhesus macaques infected with the CCR5-tropic SHIV AD8 generate cross-reactive antibodies that neutralize multiple HIV-1 strains. Proc Natl Acad Sci U S A. 2012;109(48):19769-74. 23129652 10.1073/pnas.1217443109 3511737
39. Sundling C Li Y Huynh N : High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. Sci Transl Med. 2012;4(142):142ra96. 22786681 10.1126/scitranslmed.3003752
40. Sundling C Forsell MN O'Dell S : Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J Exp Med. 2010;207(9):2003-17. 20679401 10.1084/jem.20100025 2931166 F1000 Recommendation
41. Sundling C Zhang Z Phad GE : Single-cell and deep sequencing of IgG-switched macaque B cells reveal a diverse Ig repertoire following immunization. J Immunol. 2014;192(8):3637-44. 24623130 10.4049/jimmunol.1303334 3993955
42. Phad GE Vázquez Bernat N Feng Y : Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization. J Immunol. 2015;194(12):5903-14. 25964491 10.4049/jimmunol.1500122 4458414 F1000 Recommendation
43. Tran K Poulsen C Guenaga J : Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proc Natl Acad Sci U S A. 2014;111(7):E738-47. 24550318 10.1073/pnas.1319512111 3932900 F1000 Recommendation
44. Julien J Lee JH Ozorowski G : Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens. Proc Natl Acad Sci U S A. 2015;112(38):11947-52. 26372963 10.1073/pnas.1507793112 4586835
45. Lefranc MP : Nomenclature of the human immunoglobulin heavy (IGH) genes. Exp Clin Immunogenet. 2001;18(2):100-16. 11340299 10.1159/000049189
46. Breden F Lepik C Longo NS : Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. PLoS One. 2011;6(3):e16857. 21479208 10.1371/journal.pone.0016857 3068138
47. Ledgerwood JE Coates EE Yamshchikov G : Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol. 2015;182(3):289-301. 26332605 10.1111/cei.12692 4636891 F1000 Recommendation
48. Caskey M Klein F Lorenzi JC : Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522(7557):487-91. 25855300 10.1038/nature14411 F1000 Recommendation
49. McCoy LE Falkowska E Doores KJ : Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies. PLoS Pathog. 2015;11(8):e1005110. 26267277 10.1371/journal.ppat.1005110 4534392 F1000 Recommendation
50. Webb NE Montefiori DC Lee B : Dose-response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies. Nat Commun. 2015;6:8443. 26416571 10.1038/ncomms9443 4588098 F1000 Recommendation
51. Loos A Gach JS Hackl T : Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants. Proc Natl Acad Sci U S A. 2015;112(41):12675-80. 26417081 10.1073/pnas.1509090112 4611627 F1000 Recommendation
52. Rosenberg Y Sack M Montefiori D : Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systems. PLoS One. 2013;8(3):e58724. 23533588 10.1371/journal.pone.0058724 3606348
53. Qiu X Audet J Wong G : Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med. 2012;4(138):138ra81. 22700957 10.1126/scitranslmed.3003876
54. Olinger GG Jr Pettitt J Kim D : Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A. 2012;109(44):18030-5. 23071322 10.1073/pnas.1213709109 3497800
55. van Gils MJ Sanders RW : In vivo protection by broadly neutralizing HIV antibodies. Trends Microbiol. 2014;22(10):550-1. 25169020 10.1016/j.tim.2014.08.006
56. Burton SL Kilgore KM Smith SA : Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses. Proc Natl Acad Sci U S A. 2015;112(34):10780-5. 26261312 10.1073/pnas.1509731112 4553804
57. Fouts TR Bagley K Prado IJ : Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. Proc Natl Acad Sci U S A. 2015;112(9):E992-9. 25681373 10.1073/pnas.1423669112 4352796 F1000 Recommendation
58. Carnathan DG Wetzel KS Yu J : Activated CD4 +CCR5 + T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques. Proc Natl Acad Sci U S A. 2015;112(2):518-23. 25550504 10.1073/pnas.1407466112 4299179
59. Lewis GK DeVico AL Gallo RC : Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development. Proc Natl Acad Sci U S A. 2014;111(44):15614-21. 25349379 10.1073/pnas.1413550111 4226080 F1000 Recommendation
60. Saunders KO Wang L Joyce MG : Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. J Virol. 2015;89(16):8334-45. 26041300 10.1128/JVI.00908-15
61. Balazs AB Ouyang Y Hong CM : Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med. 2014;20(3):296-300. 24509526 10.1038/nm.3471 3990417
62. Gardner MR Kattenhorn LM Kondur HR : AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature. 2015;519(7541):87-91. 25707797 10.1038/nature14264 4352131 F1000 Recommendation
63. Choe H Li W Wright PL : Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell. 2003;114(2):161-70. 12887918 10.1016/S0092-8674(03)00508-7 F1000 Recommendation
64. Farzan M Mirzabekov T Kolchinsky P : Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell. 1999;96(5):667-76. 10089882 10.1016/S0092-8674(00)80577-2
65. Farzan M Choe H Vaca L : A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J Virol. 1998;72(2):1160-4. 9445013 124591
66. Huang C Venturi M Majeed S : Structural basis of tyrosine sulfation and V H-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci U S A. 2004;101(9):2706-11. 14981267 10.1073/pnas.0308527100 365685 F1000 Recommendation
67. Xiang SH Farzan M Si Z : Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody. J Virol. 2005;79(10):6068-77. 15857992 10.1128/JVI.79.10.6068-6077.2005 1091675
68. Bonsignori M Pollara J Moody MA : Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol. 2012;86(21):11521-32. 22896626 10.1128/JVI.01023-12 3486290 F1000 Recommendation
69. Santra S Tomaras GD Warrier R : Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathog. 2015;11(8):e1005042. 26237403 10.1371/journal.ppat.1005042 4523205
70. Acharya P Tolbert WD Gohain N : Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. J Virol. 2014;88(21):12895-906. 25165110 10.1128/JVI.02194-14 4248932
71. Lewis GK Finzi A DeVico AL : Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1. Viruses. 2015;7(9):5115-32. 26393642 10.3390/v7092856 4584300
72. Zolla-Pazner S : A critical question for HIV vaccine development: which antibodies to induce? Science. 2014;345(6193):167-8. 25013066 10.1126/science.1256526 4481191 F1000 Recommendation
73. Miglietta R Pastori C Venuti A : Synergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones. J Transl Med. 2014;12:346. 25496375 10.1186/s12967-014-0346-3 4274758